SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as the community rallies to maintain visibility and momentum while working through technical ticker issues on platform aggregators. Holders are actively coordinating on social channels to foster organic growth and build a long-term community project focused on sustainability and transparency.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community eagerly awaits the official reveal of the ES9 luxury SUV, which many expect to be a major catalyst for future growth and market share expansion. Investors are actively discussing the company's aggressive technological push and strong delivery momentum, fueling intense debate over potential institutional rotation and the ongoing battle between long-term bulls and short sellers.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate the impact of agentic AI competition against the company's strong fundamentals and established enterprise role. While the community remains polarized by recent volatility and technical support levels, many are focused on the upcoming product showcase as a potential catalyst to shift the narrative and challenge short interest.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals is experiencing significant volatility and heavy trading volume as investors react to a strategic pivot that includes a 40% workforce reduction and an intensified focus on its core ovarian cancer drug trial. Community sentiment is deeply polarized, with active discussions debating whether the stock is a deep-value buyout target trading below its cash-on-hand valuation or a speculative gamble facing long-term dilution risks.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon is trending due to speculative M&A headlines involving a potential multibillion-dollar buyout offer from Sun Pharma, leading to intense social media debate over deal credibility and the company's significant debt load. Traders are closely monitoring the high volume and volatility as they weigh the binary risk of a deal announcement against the company's fundamental challenges.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant volatility and social media attention driven by speculative rumors regarding potential partnerships and high trading volume. While some community members view the token as a promising decentralized platform for the music industry, others are cautious about potential supply releases and the risks of a classic pump-and-dump scenario.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging as investors anticipate the upcoming topline Phase 2/3 OptimUM-02 trial results for its lead asset, darovasertib, in metastatic uveal melanoma. The community is actively discussing the potential for an accelerated approval filing and a commercial-stage transition, with many traders closely monitoring for high-volume price action and potential institutional accumulation ahead of the data release.

Spire Global, Inc. collects space-based data using a proprietary constellation of low earth multi-use receiver nanosatellites. Its software analytics generate proprietary data, insights and predictive analytics for its customers through a subscription model. The company was founded by Peter Platzer in August 2012 and is headquartered in Vienna, VA.

Spire Global Inc - Ordinary Shares - Class A

Spire Global is trending due to significant institutional interest and anticipation of a major recovery, bolstered by its zero-debt position, recurring revenue model, and potential participation in high-value government defense programs like the S.H.I.E.L.D. contract. Community members are actively discussing a potential short squeeze, rotating capital from the broader space sector, and expressing frustration over management's financial reporting delays, even as they eye a major breakout toward higher price targets.

Arbitrum is one of the leading Ethereum scaling solutions bringing cheap transactions to tens of thousands of users in an environment that feels very similar to Ethereum. It is an optimistic rollup and the leading L2 in terms of TVL. Some of the largest dApps live on Arbitrum include GMX, Radiant, Uniswap V3, and Gains Network.

Arbitrum

Arbitrum is currently seeing significant community interest driven by its expanding role in Real World Asset (RWA) tokenization, specifically following reports of major financial institutions and platforms leveraging its infrastructure. Investors are actively debating the token's long-term value capture potential versus concerns regarding ongoing token supply unlocks and price volatility.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is experiencing heightened market activity driven by institutional accumulation and growing sentiment that the ecosystem serves as a high-performance alternative to established L1 networks. Investors are actively discussing upcoming infrastructure milestones and ETF developments while debating whether current price levels represent an oversold opportunity for long-term accumulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Assertio Holdings, Inc. (NASDAQ: ASRT)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Assertio Holdings, Inc. (NASDAQ: ASRT) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Assertio...

Assertio Holdings, Inc. (NASDAQ:ASRT) Receives Average Rating of "Hold" from Brokerages

Shares of Assertio Holdings, Inc. (NASDAQ:ASRT - Get Free Report) have received an average rating of "Hold" from the five analysts that are currently covering the firm, Marketbeat Ratings reports...

Lake Street Capital Reiterates "Hold" Rating for Assertio (NASDAQ:ASRT)

Lake Street Capital reiterated a "hold" rating and set a $18.00 price target (down from $45.00) on shares of Assertio in a research note on Thursday...

Does Assertio (ASRT) Have the Potential to Rally 115.05% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 115.1% in Assertio (ASRT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this year.

Assertio (NASDAQ:ASRT) Earns "Neutral" Rating from HC Wainwright

HC Wainwright reissued a "neutral" rating and issued a $18.00 target price (down from $35.00) on shares of Assertio in a report on Thursday...

<ul class="summary-bullets"><li>The cash consideration represents a 3% discount to the stock’s closing price on Tuesday.</li><li>The company didn’t elaborate on the value of the CVR but said that it is related to potential future milestones for its Sprix nasal spray.&nbsp;</li><li>The transaction, approved by the board of directors of both companies, is expected to close in the second quarter of 2026.</li></ul>Shares of Assertio Holdings, Inc. (ASRT) fell by over 1% after-hours on Wednesday after the company said that it has entered into an agreement to be acquired by Garda Therapeutics for a total cash consideration of $125.1 million.Under the deal, Garda will pay Assertio shareholders $18 per share in cash and a contingent value right (CVR). The cash consideration represents a 3% discount to the stock’s closing price on Tuesday.The company didn’t elaborate on the value of the CVR but said that it is related to potential future milestones for its Sprix nasal spray.The transaction, approved by the board of directors of both companies, is expected to close in the second quarter of 2026 and is subject to customary closing conditions, the pharmaceutical company said. Assertio’s common stock will no longer be listed for trading on Nasdaq following the closing of the deal, which follows the strategic review process initiated by the company in the first quarter of 2025.<h2 class="st-heading-2">Window Shop Period</h2>Assertio also said on Wednesday that its buyout agreement includes a 20-day “window-shop” period, meaning that the company is free to engage with other parties who may provide superior value in the period.A reduced breakup fee would apply if Assertio’s board terminates its agreement with Garda in favor of a superior bid during the period.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ASRT stock stayed within ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.Stocktwits users expressed disappointment over the deal.One user called the deal a ‘robbery.’<stembedurl>https://www.stocktwits.com/TikStockTok/message/649766893</stembedurl>Another user reiterated the prior user’s stance.<stembedurl>https://www.stocktwits.com/Chrissytina/message/649766497</stembedurl><a href="https://stocktwits.com/symbol/ASRT">ASRT stock</a> has gained nearly 130% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-chinese-rival-beat-it-with-first-us-long-haul-electric-truck-delivery/cZJf7VDRIAA">Tesla’s Chinese Rival Beat It With First US Long Haul Electric Truck Delivery — What Does This Mean For The EV Giant?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

ASRT Stock Drops After-Hours On Discounted Buyout Deal — Retail Calls It A ‘Robbery’ 

Under the deal, Garda Therapeutics will pay Assertio shareholders $18 per share in cash and a contingent value right.

Equity

Under the deal, Garda Therapeutics will pay Assertio shareholders $18 per share in cash and a contingent value right.


Assertio Announces Agreement to be Acquired by Garda Therapeutics

Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), today announced a definitive agreement (the Garda Agreement) to be acquired by Garda Therapeutics (Garda or the Buyer) for $18 per...

TSP Capital Management Group LLC Has $227,000 Position in Assertio Holdings, Inc. $ASRT

TSP Capital Management Group LLC reduced its holdings in Assertio Holdings, Inc. (NASDAQ:ASRT - Free Report) by 92.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 25,056 shares of the company's stock after selling 291,819 shares during...

Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?

Assertio (ASRT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$2.10	--	--	N/A
Q4 '25	-$3.12	-$1.86	40.43%	BEAT
Q3 '25	-$0.09	$1.65	2041.18%	BEAT
Q2 '25	-$0.09	-$0.17	-88.89%	MISSED
Q1 '25	-$0.06	-$0.14	-133.33%	MISSED

ASRT
Assertio Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ASRT News

ASRTAssertio Holdings Inc